World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
37883
World Ranking
10374
National Ranking
5337

Overview

Carol Aghajanian is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research focuses largely on medicine, with significant contributions to biochemistry, genetics, and molecular biology. Within these fields, their work extends into key subfields including reproductive medicine, oncology, obstetrics and gynecology, molecular biology, and genetics.

The primary topics covered by their research include ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, and genetic factors in colorectal cancer.

Carol Aghajanian has published extensively, with a strong presence in the following venues:

  • Gynecologic Oncology (98 publications)
  • Journal of Clinical Oncology (45 publications)
  • International Journal of Gynecological Cancer (11 publications)
  • Clinical Cancer Research (9 publications)
  • Annals of Oncology (9 publications)

Their recent research papers include:

  • Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer, 2023, New England Journal of Medicine
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients, 2022, Cell
  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer, 2020, Journal of Clinical Oncology
  • Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial, 2022, Journal of Clinical Oncology
  • Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39), 2021, Journal of Clinical Oncology

Frequent collaborators in Carol Aghajanian's work include:

  • Britta Weigelt
  • Nadeem R. Abu-Rustum
  • Roisin E. O'Cearbhaill
  • Rachel N. Grisham
  • Alexia Iasonos

Best Publications

  • Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim

  • OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Carol Aghajanian;Stephanie V. Blank;Barbara A. Goff;Patricia L. Judson

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian

  • Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

    Martee L. Hensley;Robert Maki;E. Venkatraman;Gennifer Geller

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

    Dennis S. Chi;Eric L. Eisenhauer;Oliver Zivanovic;Yukio Sonoda

  • A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

    Carol Aghajanian;Steven Soignet;Don S. Dizon;Christine S. Pien

  • Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient

    Alejandro Jiménez-Sánchez;Danish Memon;Stephane Pourpe;Harini Veeraraghavan

  • The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center.

    Nadeem R. Abu-Rustum;Kaled Alektiar;Alexia Iasonos;Gali Lev

  • Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

    Vicky Makker;Drew Rasco;Nicholas J Vogelzang;Marcia S Brose

  • Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.

    Dennis S. Chi;Kristina McCaughty;John P. Diaz;Jae Huh

  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

    Vicky Makker;Matthew H. Taylor;Carol Aghajanian;Ana Oaknin

  • The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.

    Eric L. Eisenhauer;Nadeem R. Abu-Rustum;Yukio Sonoda;Douglas A. Levine

  • Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer

    Krishnansu S. Tewari;Robert A. Burger;Danielle Enserro;Barbara M. Norquist

  • Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

    Carol Aghajanian;Michael W. Sill;Kathleen M. Darcy;Benjamin Greer

  • A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study

    Robert L. Coleman;Michael W. Sill;Katherine Bell-McGuinn;Carol Aghajanian

  • Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

    Paul Sabbatini;Takemasa Tsuji;Luis Ferran;Erika Ritter

  • Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

    Carol Aghajanian;Barbara Goff;Lawrence R. Nycum;Yan V. Wang

  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

    Bastien Nguyen;Christopher Fong;Anisha Luthra;Shaleigh A. Smith

Frequent Co-Authors

Nadeem R. Abu-Rustum
Nadeem R. Abu-Rustum Memorial Sloan Kettering Cancer Center
Dennis S. Chi
Dennis S. Chi Memorial Sloan Kettering Cancer Center
Richard R. Barakat
Richard R. Barakat Northwell Health
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
David M. Hyman
David M. Hyman Memorial Sloan Kettering Cancer Center
Robert A. Soslow
Robert A. Soslow Memorial Sloan Kettering Cancer Center
Yukio Sonoda
Yukio Sonoda Memorial Sloan Kettering Cancer Center
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine but want flexible options or alternate career paths, there are many online healthcare degrees to explore. For those eager to start a nursing career, you might be looking for the easiest rn program to get into or seeking nursing school that don't require teas to simplify the admissions process.

Beyond direct patient care, non-clinical roles are a great alternative. Medical billing and coding online schools prepare students for essential administrative jobs, often allowing you to work remotely. If you’re interested in leadership roles within healthcare settings, a healthcare administration degree online accredited can help accelerate your path to upper management.

These online programs are designed to fit your lifestyle, with options that require no entrance exams and offer flexible schedules. This makes it easier to balance education with other commitments while still progressing toward a rewarding healthcare career.

Best Scientists Citing Carol Aghajanian

Trending Scientists

Recently Published Articles